Net shares · 365d
-94.8K
0 buy · 94.8K sell
Net value · 365d
-$20.4M
$0 in · $20.4M out
Sentiment · 365d
Net selling
0% buying · 100% selling
Open-market trades · 365d
5
0 buy · 94.8K sell
Trading track record · all companies
Not enough open-market trades to chart a track record yet.
Running net of open-market buys − sells across every company. Tap the line or a marker for details. ▲ buy · ▼ sell.
Transactions · 365d
-
JNJ Sell·S
EVP, Innovative Medicine, R&D
$13.1M
53.9K sh · $243.00 avg · 3 lots
Own -81%
-
JNJ Sell·S
EVP, Innovative Medicine, R&D
$4.2M
21.7K sh · $192.71
Own -67%
-
JNJ Sell·S
EVP, Innovative Medicine, R&D
$3.1M
19.1K sh · $163.55
Own -64%
| Date▾ | Ticker | Type | Shares | Value |
|---|---|---|---|---|
| Feb 17, 2026 | JNJ | Sell S | 53.9K3 lots | $13.1M |
| Oct 17, 2025 | JNJ | Sell S | 21.7K | $4.2M |
| Jul 17, 2025 | JNJ | Sell S | 19.1K | $3.1M |
Buy Sell Non-market (grant · exercise · gift)
About REED JOHN C
This profile aggregates every SEC Form 4 insider transaction reported by REED JOHN C across all companies they trade. Open-market purchases (code P) and sales (code S) are the highest-signal, discretionary trades; grants (A), option exercises (M) and gifts (G) reflect compensation rather than conviction and carry no market price. Figures cover the selected period and update as new filings are ingested.